Company: AEMD
Filing Date: 2025-02-12
Form Type: 10-Q
Source: 0001683168-25-000960
Chunk: 19

Company: AETHLON MEDICAL INC
Filing Date: 2025-02-12
Form: 10-Q
Item: Item 1
Chunk 19
---
 
     150,819  
     167,973 
  
    Accrued separation expenses 
     555,314  
     310,211 
  
    Accrued Board travel and consulting Fees 
     7,516  
     – 
  
    Total due to related parties 
    $781,899  
    $546,434 

7. STOCK COMPENSATION

The following tables summarize share-based compensation
expenses relating to RSUs and stock options and the effect on basic and diluted loss per common share during the three- and nine-month
periods ended December 31, 2024 and 2023:

    Schedule of share-based compensation
expense 

    Three Months  Ended  December 31,  2024  
    Three Months  Ended  December 31,  2023  
    Nine Months  Ended December 31, 2024  
    Nine Months  Ended December 31, 2023 
  
    Vesting of stock options and restricted stock units 
    $89,970  
    $572,955  
    $342,791  
    $1,080,250 
  
    Total stock-based compensation expense 
    $89,970  
    $572,955  
    $342,791  
    $1,080,250 

    Weighted average number of common shares outstanding – basic and diluted 
     13,962,266  
     2,516,511  
     11,801,655  
     2,477,282 

    Basic and diluted loss per common share attributable to stock-based compensation expense 
    $(0.01) 
    $(0.23) 
    $(0.03) 
    $(0.44)

All of the stock-based compensation expense recorded
during the nine months ended December 31, 2024 and 2023, an aggregate of $342,791 and $1,080,250, respectively, is included in payroll
and related expense in the accompanying condensed consolidated statements of operations. Stock-based compensation expense recorded during
each of the nine months ended December 31, 2024 and 2023 represented an impact on basic and diluted loss per common share of $(0.03) and
$(0.44), respectively.

     14 

Stock Option and RSU Activity

We did not issue any stock options during the
nine months ended December